CR20110380A - Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266) - Google Patents

Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Info

Publication number
CR20110380A
CR20110380A CR20110380A CR20110380A CR20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A
Authority
CR
Costa Rica
Prior art keywords
treatment
divisional
exp
cellular growth
abnormal cellular
Prior art date
Application number
CR20110380A
Other languages
English (en)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR20110380A publication Critical patent/CR20110380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula I en la que R2- R4 son como se han definido en esta memoria. Tales nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en los mamíferos. Esta invención se refiere también a un método de uso de tales compuestos en el tratamiento del crecimiento celular anormal en los mamíferos especialmente en los seres humanos, y a composiciones farmacéuticas que contienen tales compuestos.
CR20110380A 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266) CR20110380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43567002P 2002-12-20 2002-12-20
US50074203P 2003-09-05 2003-09-05

Publications (1)

Publication Number Publication Date
CR20110380A true CR20110380A (es) 2011-08-08

Family

ID=32685406

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8266A CR8266A (es) 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR20110380A CR20110380A (es) 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR8266A CR8266A (es) 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Country Status (31)

Country Link
US (4) US7109335B2 (es)
EP (1) EP1625121B1 (es)
AP (1) AP2385A (es)
AR (1) AR043682A1 (es)
AT (1) ATE458731T1 (es)
AU (2) AU2003285614B2 (es)
CA (1) CA2529611C (es)
CR (2) CR8266A (es)
CY (1) CY1110069T1 (es)
DE (1) DE60331479D1 (es)
DK (1) DK1625121T3 (es)
DO (1) DOP2003000793A (es)
EA (1) EA013248B1 (es)
EC (1) ECSP066406A (es)
ES (1) ES2338545T3 (es)
GE (1) GEP20084357B (es)
IL (1) IL172047A (es)
MX (1) MXPA06002608A (es)
MY (1) MY142109A (es)
NL (1) NL1025067C2 (es)
NZ (1) NZ543719A (es)
OA (1) OA13309A (es)
PA (1) PA8593001A1 (es)
PE (1) PE20041016A1 (es)
PL (1) PL379330A1 (es)
PT (1) PT1625121E (es)
RS (1) RS20060097A (es)
SI (1) SI1625121T1 (es)
TN (1) TNSN06074A1 (es)
TW (1) TWI283673B (es)
WO (1) WO2004056807A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06002608A (es) 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EA200601796A1 (ru) * 2004-05-14 2007-04-27 Пфайзер Продактс, Инк. Пиримидиновые производные для лечения аномального клеточного роста
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
MXPA06015170A (es) * 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
ES2391783T3 (es) * 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2673125C (en) * 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102007010801A1 (de) * 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
EA200901249A1 (ru) * 2007-03-16 2010-04-30 Юниверсити Оф Флорида Ресерч Фаундэйшн, Инк. Ингибиторы связывания протеинкиназ
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
BRPI0814432A2 (pt) 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
CL2009000600A1 (es) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
ES2628438T3 (es) * 2011-11-29 2017-08-02 Genentech, Inc. Derivados de aminopirimidina como moduladores de LRRK2
CA2860095A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
WO2022214009A1 (zh) * 2021-04-08 2022-10-13 杭州阿诺生物医药科技有限公司 一种高活性的hpk1激酶抑制剂

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4131184A1 (de) 1991-09-19 1993-03-25 Bayer Ag Wasserbasierte, loesungsmittel- und emulgatorfreie mikrobizide wirkstoffkombination
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE69329027T2 (de) 1992-05-22 2001-03-22 E.I. Du Pont De Nemours And Co., Wilmington Fungizide imidazolinone
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
MX9802383A (es) 1995-10-02 1998-08-30 Hoffmann La Roche Derivados de pirimidina como antagonistas del receptor 5ht26.
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998005661A1 (en) 1996-08-06 1998-02-12 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
NZ334213A (en) 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
DE19701931C1 (de) 1997-01-21 1998-05-28 Siemens Ag Verfahren zur Detektion von Synchronizität zwischen mehreren digitalen Meßreihen mit Hilfe eines Rechners
EP1754703A3 (en) 1997-02-19 2007-02-28 Berlex, Inc. N-Heterocyclic derivatives as nos inhibitors
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
UA72881C2 (uk) 1997-11-11 2005-05-16 Пфайзер Продактс Інк. Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
EP2896612A1 (en) 1998-09-29 2015-07-22 Wyeth Holdings LLC Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PL202873B1 (pl) 2000-03-13 2009-07-31 Wyeth Corp Zastosowanie związków cyjanochinoliny do leczenia lub hamowania polipów okrężnicy
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU2001269291A1 (en) 2000-07-07 2002-02-05 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
EP1311500A2 (en) 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
EP1309587B1 (en) 2000-08-09 2008-12-31 AstraZeneca AB Cinnoline compounds
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
EE05387B1 (et) 2000-08-21 2011-02-15 Astrazenecaab KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
PT1343782E (pt) 2000-12-21 2009-06-29 Smithkline Beecham Corp Pirimidinoaminas como moduladores de angiogénese
ES2320204T3 (es) 2001-05-29 2009-05-20 Bayer Schering Pharma Aktiengesellschaft Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos.
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7087614B2 (en) 2001-06-19 2006-08-08 Bristol-Myers Squibb Co. Pyrimidine inhibitors of phosphodiesterase (PDE) 7
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04007495A (es) 2002-02-05 2004-11-10 Wyeth Corp Proceso para sintesis de acidos n-acil2-amino-4-alcoxi-5-nitrobenzoicos.
DE10205336A1 (de) 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte Biphenylderivate
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2311749T3 (es) 2002-12-20 2009-02-16 SOSEI R&D LTD. Benzoxazocinas y su utilizacion como inhibidores de la recaptacion de monoamina.
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06002608A (es) * 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
RU2315759C2 (ru) * 2003-09-05 2008-01-27 Пфайзер Продактс Инк. Селективный синтез cf3-замещенных пиримидинов
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NZ543719A (en) 2007-01-26
AU2009208172B2 (en) 2011-06-16
CR8266A (es) 2007-01-18
IL172047A (en) 2012-04-30
TW200426148A (en) 2004-12-01
AP2385A (en) 2012-03-23
AU2003285614B2 (en) 2009-05-14
GEP20084357B (en) 2008-04-29
US20080182840A1 (en) 2008-07-31
EP1625121B1 (en) 2010-02-24
ATE458731T1 (de) 2010-03-15
PA8593001A1 (es) 2005-02-04
NL1025067C2 (nl) 2005-02-15
EA200600122A1 (ru) 2006-06-30
PE20041016A1 (es) 2004-12-30
OA13309A (en) 2007-04-13
PL379330A1 (pl) 2006-08-21
US7674796B2 (en) 2010-03-09
CA2529611A1 (en) 2004-07-08
EP1625121A1 (en) 2006-02-15
IL172047A0 (en) 2009-02-11
US7351712B2 (en) 2008-04-01
AR043682A1 (es) 2005-08-10
AU2009208172A1 (en) 2009-09-10
RS20060097A (en) 2008-11-28
US20060281774A1 (en) 2006-12-14
MY142109A (en) 2010-09-15
CA2529611C (en) 2009-12-15
US7741336B2 (en) 2010-06-22
TWI283673B (en) 2007-07-11
CY1110069T1 (el) 2015-01-14
EA013248B1 (ru) 2010-04-30
US7109335B2 (en) 2006-09-19
SI1625121T1 (sl) 2010-04-30
ES2338545T3 (es) 2010-05-10
TNSN06074A1 (en) 2007-10-03
MXPA06002608A (es) 2007-01-23
PT1625121E (pt) 2010-03-11
ECSP066406A (es) 2006-09-18
US20050009853A1 (en) 2005-01-13
AU2003285614A1 (en) 2004-07-14
DK1625121T3 (da) 2010-05-10
WO2004056807A1 (en) 2004-07-08
AP2005003438A0 (en) 2005-12-31
US20080300234A1 (en) 2008-12-04
NL1025067A1 (nl) 2004-06-22
DE60331479D1 (de) 2010-04-08
DOP2003000793A (es) 2011-07-31

Similar Documents

Publication Publication Date Title
CR20110380A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
UY28894A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28150A1 (es) Agentes terapeuticos
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP045146A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
UY28695A1 (es) Derivados de difenilazetidona
SV2006002089A (es) Nuevos imidazoles ref. docket 18699 (pc26195a)
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
PA8589801A1 (es) Aminoalcoxiindoles
UY28136A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
NI200500205A (es) "derivados de pirimidina para el tratamiento del crecimiento celular anorma."
AR036110A1 (es) Eurotinona y derivados de la misma, procedimiento para su preparacion, un microorganismo, composiciones farmaceuticas, procedimiento para su produccion, el uso de dichos derivados y composiciones para la preparacion de medicamentos, y uso de dicho microorganismo
CL2004000744A1 (es) Metodo para preparar derivados de fenilaminoquinazolinas; compuesto intermediario; y su metodo de preparacion.
AR033457A1 (es) Compuesto de piperazina, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para prepararlo
AR036680A1 (es) Procedimiento para preparar derivados de heterocicloalquilsulfonilpirazol y compuestos utiles en su preparacion
DOP2003000786A (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal.
DOP2005000086A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
UY28131A1 (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal
CU23712B7 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)